Literature DB >> 24655910

[Cardiovascular effects and safety of glucose-lowering drugs: current situation].

L Masmiquel1.   

Abstract

Diabetes mellitus is an independent cardiovascular risk factor. Therefore, in addition to normalising blood glucose, the aim of the treatment for diabetes mellitus should be to prevent cardiovascular complications. However, the evidence available on the cardio-protective role of the different glucose-lowering drugs is scarce and poor, particularly as regards with the risk of major cardiovascular events. In this context, the regulatory agencies have modified the regulations for the approval of glucose-lowering drugs, now requiring to demonstrate the glucose-lowering effect together with a robust assessment of the cardiovascular safety. The aim of this work is to review the cardiovascular effects of the different glucose-lowering drugs, focusing on their impact on the risk of major cardiovascular events.
Copyright © 2012 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España. All rights reserved.

Entities:  

Keywords:  Anti-diabetics; Antidiabéticos; Cardiovascular risk; Diabetes mellitus; Eventos cardiovasculares mayores; Glucose-lowering drugs; Hipoglucemiantes; Major cardiovascular events; Riesgo cardiovascular

Mesh:

Substances:

Year:  2013        PMID: 24655910     DOI: 10.1016/j.semerg.2012.12.001

Source DB:  PubMed          Journal:  Semergen        ISSN: 1138-3593


  1 in total

1.  Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.

Authors:  Ya-Ru Wu; Xiao-Yun Shi; Chun-Yan Ma; Yue Zhang; Rui-Xia Xu; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2019-11-09       Impact factor: 9.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.